Name | Number of supported studies | Average coverage | |
---|---|---|---|
type I pneumocyte | 5 studies | 46% ± 10% | |
type II pneumocyte | 5 studies | 23% ± 5% | |
ciliated cell | 3 studies | 29% ± 8% | |
club cell | 3 studies | 34% ± 8% | |
astrocyte | 3 studies | 30% ± 18% |
Insufficient scRNA-seq data for expression of GPR39 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 107.89 | 328 / 328 | 90% | 4.69 | 161 / 178 |
stomach | 89% | 182.76 | 320 / 359 | 94% | 6.70 | 270 / 286 |
kidney | 98% | 91.57 | 87 / 89 | 83% | 3.52 | 751 / 901 |
liver | 99% | 112.72 | 223 / 226 | 81% | 2.51 | 330 / 406 |
lung | 97% | 170.47 | 562 / 578 | 76% | 6.11 | 882 / 1155 |
intestine | 59% | 126.00 | 574 / 966 | 96% | 7.17 | 506 / 527 |
thymus | 93% | 51.91 | 610 / 653 | 59% | 1.21 | 359 / 605 |
bladder | 62% | 119.14 | 13 / 21 | 81% | 5.17 | 409 / 504 |
breast | 65% | 51.24 | 298 / 459 | 78% | 3.59 | 868 / 1118 |
esophagus | 39% | 18.06 | 566 / 1445 | 72% | 3.69 | 131 / 183 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.25 | 1 / 1 |
skin | 82% | 46.64 | 1491 / 1809 | 6% | 0.29 | 27 / 472 |
prostate | 72% | 27.78 | 176 / 245 | 16% | 0.25 | 79 / 502 |
ovary | 6% | 1.79 | 10 / 180 | 82% | 3.21 | 351 / 430 |
uterus | 15% | 7.61 | 25 / 170 | 69% | 2.81 | 315 / 459 |
tonsil | 0% | 0 | 0 / 0 | 71% | 2.83 | 32 / 45 |
brain | 53% | 16.43 | 1405 / 2642 | 9% | 0.30 | 66 / 705 |
adipose | 24% | 7.50 | 285 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 22% | 7.77 | 300 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 0% | 0 | 0 / 258 | 6% | 0.17 | 13 / 230 |
heart | 1% | 0.12 | 5 / 861 | 0% | 0 | 0 / 0 |
spleen | 0% | 0.10 | 1 / 241 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.06 | 2 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0.02 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0005886 | Cellular component | plasma membrane |
GO_0004930 | Molecular function | G protein-coupled receptor activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | GPR39 |
Protein name | Uncharacterized protein GPR39 Alternative protein GPR39 G-protein coupled receptor 39 GPR39 protein |
Synonyms | |
Description | FUNCTION: Zinc-sensing receptor that can sense changes in extracellular Zn(2+), mediate Zn(2+) signal transmission, and participates in the regulation of numerous physiological processes including glucose homeostasis regulation, gastrointestinal mobility, hormone secretion and cell death . Activation by Zn(2+) in keratinocytes increases the intracellular concentration of Ca(2+) and activates the ERK/MAPK and PI3K/AKT signaling pathways leading to epithelial repair . Plays an essential role in normal wound healing by inducing the production of cytokines including the major inflammatory cytokine IL6 via the PKC/MAPK/CEBPB pathway (By similarity). Regulates adipose tissue metabolism, especially lipolysis, and regulates the function of lipases, such as hormone-sensitive lipase and adipose triglyceride lipase (By similarity). Plays a role in the inhibition of cell death and protects against oxidative, endoplasmic reticulum and mitochondrial stress by inducing secretion of the cytoprotective pigment epithelium-derived growth factor (PEDF) and probably other protective transcripts in a GNA13/RHOA/SRE-dependent manner . Forms dynamic heteroreceptor complexes with HTR1A and GALR1 depending on cell type or specific physiological states, resulting in signaling diversity: HTR1A-GPR39 shows additive increase in signaling along the serum response element (SRE) and NF-kappa-B pathways while GALR1 acts as an antagonist blocking SRE . . |
Accessions | Q53RU7 L8E9W9 O43194 ENST00000329321.4 A4FVA5 |